Video

Dr. Leslie on the Encouraging Evolving Treatment Landscape in MCL

Lori A. Leslie, MD, discusses the encouraging evolving treatment landscape in mantle cell lymphoma.

Lori A. Leslie, MD, lymphoma attending, John Theurer Cancer Center, discusses the encouraging evolving treatment landscape in mantle cell lymphoma (MCL). 

It is important to note that past studies in MCL may be outdated as the field is exploding with new information, says Leslie. Prior data painted a more dismal outlook for patients with MCL that may no longer hold true given the current treatment landscape, Leslie adds. 

In recent years, many treatment advances have been implemented ​and will likely contribute to improved patient care in the future, Leslie concludes.

Related Videos
Andrew Ip, MD
Mansi R. Shah, MD
Elizabeth Buchbinder, MD
Benjamin Garmezy, MD, assistant director, Genitourinary Research, Sarah Cannon Research Institute
Alec Watson, MD
Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, break down the current treatment landscape for relapsed/refractory follicular lymphoma.
Sagar D. Sardesai, MBBS
Ashkan Emadi, MD, PhD
Matthew J. Baker, PhD
Manmeet Ahluwalia, MD, MBA, FASCO